Biotech Values

[genisi]

LY517717 - It had completed a Phase II VTE prophylaxis study in 2005 but had not made significant clinical progress since then. Moreover, there was a preclinical tox finding with it but LLY didn't reveal the species nor the type of tox. LLY has not stated that it has discontinued development of LY517717 but it doesn't look like their efforts to partner it are going well.